Best of ASH Annual Meeting & Exposition | Conference

Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH
December 27, 2020

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

Guido Lancman, MD, on the Study Design of IVIG in Patients with Multiple Myeloma Receiving Daratumumab
December 26, 2020

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.

Lisa La on the Design of a Study Evaluating Diabetes in Patients with Multiple Myeloma
December 23, 2020

The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.

Peter Voorhees, MD, Discusses Updated Analysis of Phase 2 GRIFFIN Trial in MM
December 23, 2020

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

Jeffrey Wolf, MD, on Findings From a Study Investigating Therapy Changes Using MRD in Patients With Multiple Myeloma
December 19, 2020

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

Lisa La on the Next 5 Years in Multiple Myeloma Research
December 11, 2020

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

Jeffrey Wolf, MD, on Next-Generation CAR T Cell Therapy and the Future of Multiple Myeloma Treatments
December 11, 2020

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

Guido Lancman, MD, on Multiple Myeloma Treatments Being Presented at ASH
December 10, 2020

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.

Lisa La on Multiple Myeloma Research Coming Out of ASH
December 10, 2020

The clinical researcher spoke about the research that she is most excited to review at ASH this year.